Company Filing History:
1 out of 37 
1 out of 1 Years Active: 1993
Title: The Innovations of Shinzo Isojima
Introduction
Shinzo Isojima is a notable inventor based in Hyogo, Japan. He is recognized for his contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has significant implications for contraception and infertility treatments in human females.
Latest Patents
Isojima holds a patent for the monoclonal antibody NUH2, which is capable of inactivating the motility of human sperm. This antibody is produced by a hybridoma with the ATCC deposit number HB 9762. The patent also describes an isolated antigen that specifically binds to anti-human sperm antibodies, including NUH2, and comprises at least an epitope with a sialyl I structure. Additionally, the patent covers methods for using the monoclonal antibody and antigen for contraception and treating infertility in women.
Career Highlights
Throughout his career, Isojima has worked with esteemed institutions such as the Biomembrane Institute and Hyogo Medical College. His research has contributed to advancements in reproductive health and has opened new avenues for therapeutic interventions.
Collaborations
Isojima has collaborated with notable colleagues, including Edward D. Nudelman and Tokio Kaizu. These partnerships have enriched his research and expanded the impact of his innovations.
Conclusion
Shinzo Isojima's work in developing monoclonal antibodies represents a significant advancement in biotechnology. His contributions have the potential to improve reproductive health and provide new solutions for infertility.